Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Development and validation of a questionnaire to assess delay in treatment for breast cancer

Karla Unger-Saldaña1*, Ingris Peláez-Ballestas2 and Claudia Infante-Castañeda3*

Author Affiliations

1 Faculty of Medicine, Universidad Nacional Autónoma de México & Instituto Nacional de Cancerología de México, Mexico City, Mexico

2 Rheumatology Department, Hospital General de México, Mexico City, Mexico

3 Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico

For all author emails, please log on.

BMC Cancer 2012, 12:626  doi:10.1186/1471-2407-12-626

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2407/12/626


Received:24 April 2012
Accepted:18 December 2012
Published:28 December 2012

© 2012 Unger-Saldaña et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

This study reports the reliability and validity of a questionnaire designed to measure the time from detection of a breast cancer to arrival at a cancer hospital, as well as the factors that are associated with delay.

Methods

The proposed questionnaire measures dates for estimation of the patient, provider and total intervals from detection to treatment, as well as factors that could be related to delays: means of problem identification (self-discovery or screening), the patients’ initial interpretations of symptoms, patients’ perceptions of delay, reasons for delay in initial seeking of medical care, barriers perceived to have caused provider delay, prior utilisation of health services, use of alternative medicine, cancer-screening knowledge and practices, and aspects of the social network of support for medical attention. The questionnaire was assembled with consideration for previous research results from a review of the literature and qualitative interviews of patients with breast cancer symptoms. It was tested for face validity, content validity, reliability, internal consistency, convergent and divergent validity, sensitivity and specificity in a series of 4 tests with 602 patients.

Results

The instrument showed good face and content validity. It allowed discrimination of patients with different types and degrees of delay, had quite good reliability for the time intervals (with no significant mean differences between the two measurements), and fairly good internal consistency of the item dimensions (with Cronbach’s alpha values for each dimension between 0.42 and 0.85). Finally, sensitivity and specificity were 74.68% and 48.81%, respectively.

Conclusions

To the best of our knowledge, this is the first published report of the development and validation of a questionnaire for estimation of breast cancer delay and its correlated factors. It is a valid, reliable and sensitive instrument.

Keywords:
Breast cancer; Delayed medical care; Questionnaire; Validity; Reliability

Background

Breast cancer is the most common cancer in women and the main cause of cancer-related deaths worldwide, causing approximately 2-million new cases and 500,000 deaths in 2008 [1]. It is also the main cause of cancer-related deaths among women in Mexico, with close to 14,000 new cases and 5,000 deaths per year [1].

In Mexico, as in other developing countries, breast cancer survival rates are much lower than in developed countries, mainly because cancer is diagnosed in later stages. For instance, in the United States, 60% of breast cancer cases are diagnosed in stages 0 and I, with survival rates of 98% [2], whereas in Mexico less than 10% of patients are diagnosed in these early stages and 47% in the most advanced stages (III and IV) [3,4]. The main reasons for presentation of breast cancer patients in advanced stages in Mexico could be related to the very low participation of women in breast cancer screening tests [5], delayed help-seeking for breast cancer symptoms and barriers to accessing health care services [6].

Breast cancer total delay is defined in the literature as a span of more than three months between the discovery of symptoms by the patient and the beginning of definitive cancer treatment [7-9]. Traditionally, it has been classified in two types: patient and provider delay. Cut-points to define these intervals vary across studies, but the majority of studies have considered patient delay to be more than three months between the discovery of symptoms and the first medical consultation [7,10-12]. In turn, provider delay takes place between the first medical consultation and the beginning of definitive treatment, and the most accepted threshold is one month, although this cut-point varies across studies [13-17].

Although breast cancer treatment delay has been studied by multiple authors for years, there is no validated instrument to measure time intervals and correlated factors. Several instruments to estimate the likelihood of delay in seeking medical attention if a cancer symptom were to present have been validated in asymptomatic patients [18,19], but no studies have assessed delay among breast cancer patients. Some breast cancer delay studies refer to questionnaires based on previous study results or describe the results of pilot studies, but no validity and reliability measures are specified [20-22]. We found only one study in which the reliability and validity of self-reported symptoms and dates of diagnostic tests was measured, but this study surveyed patients with colon cancer [23], which is characterised by a completely different set of symptoms, natural history and illness behaviour compared to breast cancer [24-27]. Nonetheless, the authors found that self-reported symptoms, tests and dates were in general reliable but not necessarily valid [23].

This dearth of validated instruments that measure delay is most likely a result of the difficulties inherent in establishing the validity of time intervals for medical care for any disease [28]. These intervals are estimated based on the date of symptom discovery, the date of initial medical consultation and the date of beginning of treatment. The most problematic dates to obtain reliably are those given by the patient, as there may be recall inaccuracy [29] and response bias due to concerns about social desirability [30]. Nevertheless, it has been shown that patients commonly recall the precise time when they first discovered their symptoms [12,23,31].

Due to the known association between delay, advanced clinical stages of breast cancer and survival [32], it is important to quantify the degree of delay and its correlated factors so that targeted interventions to reduce delay can be designed. Such interventions are especially important in developing countries where the majority of patients are diagnosed in advanced stages, as in Mexico [33].

In this paper, we report the development and validation of a questionnaire designed to a) measure the time from detection of a possible breast cancer (through either patient symptoms or abnormal screening findings) to arrival at a cancer hospital and b) identify factors correlated with the delayed beginning of medical treatment.

Methods

Study design

The study protocol was approved by the scientific and ethics review boards of the Mexican National University (registry number 24–2007) and the National Cancer Institute (registry 05048TMI). The results here presented are part of a larger study that aims to quantify time intervals from the detection of a possible breast cancer to the beginning of cancer treatment and identify the main factors predicting prolongation of these intervals. This paper reports the development and validation (using standard test-construction methods) of an instrument to assess time from detection of breast cancer to arrival at a cancer hospital and possible associated factors with delayed beginning of treatment [28,34]. After the first draft of the questionnaire was written, it was tested for psychometric properties and refined in a set of 4 cross-sectional tests of different patients. The construction and validation of the questionnaire are schematised in Figure 1.

thumbnailFigure 1. Stages in the production of the breast cancer delay questionnaire. This schema summarizes the stages of construction and validation of the questionnaire.

Construction of the questionnaire

The questionnaire was built to assess time from the first identification of a breast problem that could be cancer (either through screening practices or symptoms discovered by the patient) to arrival at a cancer hospital, and possible associated factors with delayed beginning of treatment. The questionnaire was assembled with consideration for previous research results from a review of the literature and qualitative interviews of patients with breast cancer symptoms. Details of these previous study phases are published elsewhere [9,35]. Nevertheless, it is important to emphasise that the definitions and classifications of the time intervals, as well as those of the correlated factors and the methods used for their study, were critically assessed and considered in the construction of the instrument.

Furthermore, the first draft of the questionnaire included items reflecting the most common themes in the qualitative patient interviews. The instruments’ questions and response categories were phrased in simple terms and in accordance with the words used by the patients in the qualitative interviews. The items were then revised and improved after evaluation by experts in the design of questionnaires and a multidisciplinary team of advisors: a sociologist, a clinical epidemiologist and anthropologist, an oncologist, an epidemiologist and a statistician. Finally, they were tested for comprehensibility by the participants in the first pilot study.

The questionnaire was designed for application through face-to-face interviews due to the difficulties associated with self-administered research instruments in Mexico among people with little formal education [36,37], like our study participants.

The conceptual and operational definitions of the time intervals agree with the majority of studies of breast cancer delay and recent recommendations of a consensus [38]. Total interval was defined as the time from identification of the problem (either through symptoms or screening) to the beginning of cancer treatment; patient interval was defined as the time from identification of the problem to the first medical consultation; and provider interval was defined as the time from the first presentation (first medical consultation) to the beginning of cancer treatment. Date of symptom discovery and date of presentation were both obtained from the patients through the questionnaire, whereas the dates of beginning of treatment were obtained from their hospital charts.

Participants

The patients included in this study were women who were referred to the Breast Tumours Department of the Mexican National Cancer Institute (INCAN) with a probable breast cancer diagnosis. INCAN is a referral hospital that offers specialised cancer care at low costs for uninsured patients, most of whom are unemployed or informally employed.

Patients were excluded if they had received previous cancer treatment for the current breast cancer, if they had a personal history of cancer, if they were unable to participate in the interview (because of impaired hearing, inability to communicate in Spanish, or mental disability), or if they had a history of a benign breast condition that had been under medical surveillance. This last exclusion criterion was considered because the profile of women with benign breast disease has been shown to differ significantly from that of women with breast cancer [9]. Additionally, completed questionnaires were excluded from analysis if the patient did not recall one or more of the relevant dates.

Interviews

In the first pilot study, KUS conducted all of the interviews. From the second pilot study onwards, the interviewers were psychologists who were trained by KUS to standardise the interviewing process. Training consisted in a first theoretical module, a second phase of supervised practice of interviews with individuals that simulated fictitious patient stories, and a third phase where the interviewers administered the questionnaire to breast cancer patients in the presence of KUS. The patients who were interviewed in the training stage were not included in the final analysis.

New patients who arrived at the Breast Tumours Department were invited to participate while they were waiting for their first consultation with the breast specialist. The interviewer identified herself and asked the patient for verbal consent to ask her three questions (the exclusion criteria). If the patient was eligible for the study, she was then invited into a private room with the person who accompanied her to the hospital. No monetary incentives were given. The patient was given a written description of the study objectives and what her participation would consist of, including her rights to not participate. The trained interviewer read this form with the patient and relative and then offered to clarify any issues that remained ambiguous. Finally, if she was willing to participate, she was asked to sign an informed consent form, and her relative was asked to sign as a witness. After informed consent was obtained, the patient’s relative was asked to wait for the patient outside so that the interview could be done in private.

All dates were retrieved in the form of day, month and year with the aid of calendars and in relation to events that occurred during the patient’s help-seeking trajectory, including national holidays, significant news and personal events such as the participant’s birthday. Calendars were printed out, and as part of the standardised interview process, the interviewers gave each participant a calendar and asked her to recall the relevant dates as precisely as she could. This procedure enhanced recall, as the participant could deduce the date of a health event from the calendar by locating it in relation to other significant dates.

For participants who had lesions detected by screening, the date of problem identification was considered to be the date of first contact with a medical service; thus, the patient interval was 0 days. When the patient did not remember the exact date, she was asked to remember whether it was in the beginning, middle or end of the month. The beginning of the month was coded as day 5, the middle of the month as day 15, and the end of the month as day 25. If she could not be more precise, her answer was coded as day 15 (middle of the month). Some patients with several years of delay could remember only the year. These patients were asked to remember if the date was early in the year, mid-year or late in the year. These answers were coded as follows: “beginning of the year”, 15 February; “middle of the year”, 15 June; and “end of the year”, 15 November. If she remembered only the year, the answer was coded as “middle of the year”.

Participants were not directed in any way by the interviewers to obtain an answer. Part of the standardisation consisted in reading each question to the patient two times word-for-word if she did not understand the first time. If the participant still did not understand after the second time the question was asked, then the interviewers paraphrased the question. Finally, if no response was elicited after the third attempt, the interviewers marked that question as unanswered and went on to ask the next item.

Review of patient files

To quantify the total delay and provider intervals, the dates required are that of problem identification, first medical consultation and beginning of treatment. The instrument was designed to assess only the first two, since the patients were interviewed before they began cancer treatment. Therefore, the participants’ medical files were reviewed six months after the interview to obtain the date that the first cancer treatment was begun and the clinical stage of the cancer. The beginning of cancer treatment was considered as the date that the first oncologic treatment was begun, whether it was surgery, chemotherapy, radiotherapy, hormonal therapy or antibody therapy.

Procedures and measures

Sensibility analysis

Sensibility was appraised in a qualitative manner by the researchers in terms of what the instrument contains and what it does, as recommended by Feinstein [28]. The following topics were analysed: a) comprehensibility, b) replicability, c) suitability of scale, d) face validity, e) content validity, f) ease of usage and g) patient acceptance. This assessment was performed continuously throughout the different stages of the study. Items that were irrelevant or duplicated in early versions of the questionnaire were eliminated. Those that were found by respondents to be ambiguous or difficult to understand were rewritten, and some new categories were incorporated when an answer that had not been considered in the previous version was given by more than 10% of the interviewees. Finally, the item order was changed after the first and second pre-test studies to make the interview more fluent.

Reliability

External consistency or reliability was estimated with a test-retest analysis of 30 patients who participated in the second pre-test and to whom the same instrument was applied twice within a 3-month interval. Appointments for the second interview with these participants were scheduled by telephone. The second interview was arranged at a date and time that was convenient for the patient and on the same day as one of her medical appointments so that she did not have to come to the hospital only for the interview.

Best timing for questionnaire administration

Different timings for the interviews were tested to maximise patient cooperation and minimise interference with the usual institutional procedures. This was conducted in a qualitative manner by the researchers. Furthermore, the proportion of patients that reported dates with precision was compared for the participants in the test-retest.

Validity

Criterion validity was not assessed, as there is no gold-standard instrument to measure delay or the factors associated with it. Construct validity was evaluated for each questionnaire dimension by estimating internal consistency and convergent and divergent validity [28,39].

Item scoring

Responses within each item were assigned a value according to their bivariate association with the different time intervals (total, patient and provider). More points were given to the response categories associated with longer intervals, and fewer points were given to those associated with shorter intervals. For each item the response category associated negatively with delay was given a value of 0, the category with the highest positive association with delay was given the highest value, and the remaining response categories were given values in between accordingly. The assigned value for each item’s response categories depends on the number of response categories. If there were four response categories, the lowest value would be 0 and the highest 3, whereas if there were two categories the values would range only from 0 to 1. For example, the item “means of problem identification” had a score of 0 when the problem was identified through screening and 1 when it was identified through patient symptoms. To determine a score for each dimension of the questionnaire, the component item scores for each patient were summed. Finally, to determine the total questionnaire score, scores for all dimensions were added up.

Sensitivity and specificity

ROC curves were estimated for the total questionnaire scores in relation to total, patient and provider delays. As there is no gold standard, the total questionnaire score was dichotomised using the median as the cut-off point [28,39]. The intervals were also dichotomised with the following cut-off values: total delay was recorded when the total interval was equal to or greater than 180 days; and patient or provider delay was recorded when the patient or provider interval was 90 days or more. We decided to use cut-off points that are much longer than the most widely accepted thresholds in the literature because 97% of the women in our sample had total intervals greater than 90 days.

Final item selection

Bivariate analysis of each of the questionnaire items and the three time intervals was performed to identify the factors most likely to predict delays. Those items that showed the highest correlations were kept for the final version of the questionnaire. Those that were not statistically significant but hold theoretical relevance were also kept in the final version of the questionnaire. The purpose of this study was to assess the instruments’ validity and reliability, not draw conclusions regarding the relevance of each item to delay. In the next phase of the study, a multivariate analysis of a larger, multi-centre sample will allow determination of each item’s relevance and further refinement of the instrument.

Statistical analysis

Sample sizes were based on the quality criteria recommended by Terwee et al., who suggested a minimum of 50 patients for assessing construct validity and a minimum of 100 patients for assessing internal consistency [40].

Descriptive statistics were estimated to measure the participants’ sociodemographic characteristics, final diagnoses and clinical stages, as well as for the total, patient and provider intervals. The quantitative variables included mean, median, standard deviation and interquartile range; categorical variables included frequency and percentage.

To reduce the questionnaire, a correlation matrix of variables and a principal component analysis of each dimension were carried out. For pairs of variables with correlation coefficients higher than 0.70, we selected the one that explained the greatest variation according to the principal component analysis.

To evaluate test-retest reliability, a t-test for related samples was performed to compare mean differences in interval lengths between the two measurements. A correlation matrix was estimated for the remaining variables to compare responses between the first and second questionnaire applications for each individual. Furthermore, the total score obtained by each patient on the first and second application of the questionnaire was compared for each dimension.

Internal consistency was assessed through estimation of Cronbach’s alphas for each questionnaire dimension, as recommended by Terwee and collaborators [40]. Alphas equal to or greater than 0.40 (p < 0.05) were considered acceptable [34,41]. Convergent validity was assessed by estimating Spearman correlation coefficients for items comprising each domain, and divergent validity across items of different domains.

To select the final items in the instrument, bivariate associations were estimated between each questionnaire item and each of the three intervals (total, patient and provider) through Likelihood Ratio (LR) coefficients and bivariate logistic regression. Items that showed LR coefficients greater than 10 (p < 0.05) and significant ORs (p < 0.05) were considered to have statistical relevance.

Results

Description of the instrument: the breast cancer delay questionnaire

The final questionnaire is composed of two independent modules containing 68 items. These items mainly include categorical answers, Likert scales and several open-ended questions. One module assesses dates to estimate the intervals in which delay can occur. The other measures different factors predisposing to delay. The two modules are intertwined in the questionnaire to facilitate its application. In the first pilot study, we tested the two modules separately and found that it was more difficult to elicit responses. On the one hand, it was harder for the patient to recall the dates of symptom discovery and first medical consultation without having discussed how they discovered the first symptom or where they sought medical attention for their health problem. On the other hand, questions about reasons for having delayed care or barriers to accessing care required respondents to think about dates and how much time had passed.

The combined application of this instrument and a revision of patients’ clinical files to assess the dates of diagnosis confirmation and the beginning of cancer treatment allow the estimation of total, patient and provider intervals, as well as of the subintervals that compose the provider intervals: diagnosis and treatment intervals. The instrument is organised in 8 questionnaire sections that encompass 16 dimensions. Table 1 shows the questionnaire dimensions and the included items. The questionnaire in Spanish, is available for free in the BMC Cancer webpage (Additional file 1). Although the attached version of the questionnaire does not include sociodemographic items, it is certainly recommended that these are added in accordance to the context where it will be administered.

Additional file 1. The breast cancer delay questionnaire.

Format: PDF Size: 445KB Download file

This file can be viewed with: Adobe Acrobat ReaderOpen Data

Table 1. Questionnaire dimensions and items

Pre-test 1. Face and content validity (Stage 2)

The first version of the questionnaire, which comprised 129 items, was applied to 43 patients who came to the Breast Clinic of INCAN for the first time between January and May 2008 with a probable breast cancer diagnosis (Figure 1). Patient demographic, disease and delay data are summarised in Table 2. The aim of this stage was to evaluate the instrument’s sensibility [28]. The most important modifications to the questionnaire that arose from this stage were 1) rearrangement of the sequence of items to make the interview more fluent, 2) rewording of questions, 3) addition of response categories, and 4) elimination of items that showed no variation.

Table 2. Demographic and disease informationa

Pre-test 2. Item reduction, reliability and date accuracy (Stage 3)

The second draft of the questionnaire, with 112 items, was applied to 50 patients with probable breast cancer on their arrival at INCAN between June 15 and July 8, 2009. Patient demographic and disease information is shown in Table 2. After the correlation matrix of variables and principal component analysis for each questionnaire dimension were done (data not shown), the third draft of the questionnaire was reduced to 94 items.

Reliability

A test-retest was performed for 53 of the 66 final items measuring factors correlated with delay and the delay intervals. The t-test results comparing the means of the interval lengths are presented in Table 3. There were no significant mean differences between the two measurements.

Table 3. Test-retest of intervals

Questionnaire items showed quite good external consistency in general. Table 4 presents descriptive statistics for the scores obtained from each questionnaire dimension in Test 1 and Test 2. Correlations between pairs of measurements for individual items are not shown, but in summary, the results were as follows: 16 items had excellent consistency, with correlation coefficients equal to or greater than 0.75 (p<0.05); 32 items had moderate-to-good consistency, with correlation coefficients between 0.4 and 0.75 (p<0.05); and 18 had poor consistency, with coefficients less than 0.4, although as is argued in the discussion section, this finding could be an effect of the passage of time.

Table 4. Test-retest dimension scores

Best time for the interviews

After testing different moments for performing the interviews, we determined that the best moment for the interview to take place was before the patient was seen by the breast specialist for the first time after her arrival to INCAN. At this moment, patient cooperation and recall of dates and events prior to her arrival at INCAN were maximised and interference with institutional procedures was minimised. While 66.7% (20/30) were able to give a precise date for problem identification in the first interview, in the second interview (three months later), only 36.7% (11/30) were able to recall a precise date. Similarly, 83% (25/30) were able to remember the precise date of the first medical consultation in the first interview, and only 56.7% (17/30) were able to do so in the second interview.

Pre-test 3. Internal consistency (Stage 4)

125/167 new patients that arrived for the first time at the Breast Tumors Department of INCAN between July 20th and October 5th of 2009, were interviewed (Table 2). The questionnaire dimensions showed good internal consistency in this sample, with Cronbach’s alphas in the range of 0.51 to 0.90 (data not shown).

Final test. Item selection and validity assessment (Stage 5)

Five hundred and sixteen women who arrived at the Breast Clinic of INCAN between October 2009 and July 2010 were invited to participate in test 4. The sociodemographic characteristics of the 384 participants are summarised in Table 2.

The following analyses were performed with patient samples from tests 3 and 4, for a total sample size of 509 patients. Figure 2 summarises the inclusion, exclusion and elimination criteria.

thumbnailFigure 2. Patients’ inclusion, exclusion and elimination criteria. This diagram illustrates the process of invitation, exclusion, informed consent and elimination of study participants of the pretest 3 and test 4.

Final item selection

The majority of the final items that were selected had significantly high LR correlation coefficients and bivariate logistic regression ORs. Among the items with the highest associations (LR>10 and/or OR>2) with total delay were perceived medical errors (LR=26.27, p=0.000; OR=4.02, 95% CI: 2.26-7.14; p=0.000), difficulty missing work (LR=11.96, p=0.001; OR=3.39, 95% CI:1.59-7.23; p=0.002,), long waiting times for medical appointments (LR=11.96, p=0.001; OR=3.49, 95% CI:1.59-7.23; p=0.002,), having consulted more than two different health services prior to arrival at INCAN (LR=19.03, p=0.000; OR=2.78,, 95% CI:1.74-4.42; p=0.000), the patient’s reason for seeking medical help being worsening or persistence of symptoms rather than appearance (LR=13.92, p=0.000; OR=2.61,, 95% CI:1.57-4.33; p=0.000) and the patient taking longer than 30 days to talk to someone about her breast problem (LR=9.57, p=0.002; OR=2.28,, 95% CI:1.32-2.90; p=0.003). The majority of the items listed under the social network of support for medical attention were not significant. Nevertheless, they were kept because of their theoretical relevance.

Sensibility analysis

The instrument is comprehensible and replicable, but we strongly recommend that people who are to administer it receive training. The output scales have comprehensive and mutually exclusive response categories and allow discrimination of different features. The items have face validity, as they elicit the intended information, and they were well accepted and generally easily understood by both interviewers and interviewees.

Content validity was assured in the construction of the questionnaire by including items derived from the qualitative interviews and the literature and by having the appropriateness of included items reviewed by a multidisciplinary team.

The administration of the questionnaire may be time-consuming, taking in average 40 (SD=14.6) minutes. The instrument is usually more time-consuming to administer to older women and to those with no or incomplete primary school education, as these women have greater difficulty in remembering dates and understanding some questions. The instrument was, however, well accepted by patients, with only 4.4% (24/540) of those invited refusing to participate after the study was explained to them (Figure 2). Patient cooperation during the interview was good, and participants were usually highly motivated. After the interview, the majority of patients thanked the interviewer for listening to them.

The total score for the questionnaire ranged from 11 to 67 points, with a mean of 37 (SD = 11.52) points (n=509).

Construct validity

Internal consistency

The instrument has fairly good internal consistency, with Cronbach’s alpha for each dimension in the range of 0.42 to 0.85 (Table 5). Although we tried to build a scale for the items related to the social network of support, as well as for those in the health service utilisation dimension, these items had very low Cronbach’s alpha values and were therefore left disaggregated.

Table 5. Internal consistency of questionnaire scales

Convergent and divergent validity

The majority of items within the following dimensions showed moderate degrees of correlation with each other: patient’s initial interpretation of symptoms (r=0.52 – 0.72, p=0.000), reasons for delay in initial seeking of care (r= 0.21 – 0.64, p=0.000) and perceived barriers in the provider interval (r= 0.23 – 0.62, p=0.000). Items in the following dimensions correlated poorly (r ≤ 0.30): symptoms present on arrival at the cancer hospital, social-network support for seeking medical care, health service utilisation, cancer-related knowledge and cancer-screening practices. Items belonging to different dimensions in general were not correlated or were poorly correlated (r < 0.30), except for perception of patient delay, which was moderately correlated with most of the perceived reasons for patient delay and with time between identification of the problem and the first time talking to someone about it (r =0.35 – 0.74, p=0.000). Additionally, perception of provider delay was correlated with most of the perceived barriers for provider delay (r = 0.29 – 0.69, p=0.000).

Sensitivity and Specificity

The results derived from a ROC curve analysis are presented in Table 6. The questionnaire score predicted total, patient and provider delays with sensitivities of 74.68%, 66.67% and 81.17% and specificities of 48.81%, 77.70% and 20.24%, respectively. In general, it shows fair sensitivity and poor specificity, with higher specificity for patient delay than for provider delay.

Table 6. ROC Curve results of the total questionnaire score for the different delay intervals

Discussion

To the best of our knowledge, this is the first published report of the development and validation of a questionnaire for estimation of the breast cancer total, patient and provider intervals and the correlated factors with delays. Due to the association between delay and prognosis for breast cancer [32], it is important to quantify it and identify correlated factors. This is especially relevant in developing countries, where the majority of patients are diagnosed in advanced stages, as in Mexico [33].

The instrument was developed, modified and validated using standardised test-construction methods [28,34,40]. The results of the current study show that the instrument has good face validity, comprehensibility, patient acceptance, and content validity. It has acceptable internal consistency in most dimensions (considering the social nature of most of the items) and very good reliability for most items [34,41].

Although the two modules of the questionnaire were intertwined to facilitate its administration for this study, they would be easy to separate if someone wished to measure only the time intervals in another context. Nonetheless, we found that this intertwining of modules facilitated the questionnaire’s administration in our population, easing the flow of the interview.

Reliability was high for both total and patient intervals. In agreement with other studies, this shows that patients tend to recall the precise time when they first discovered their symptoms [12,31] or at least the month and year of this discovery [23]. Nevertheless, the provider interval did not show very good consistency. Because the test-retest measurements were taken with a 3-month separation, the variation in the estimation of this interval may be explained by recall bias. Apparently, memory was more affected in our participants in relation to the first medical consultation than in relation to the beginning of the problem. It is likely that the passage of time makes it harder for patients to recall dates and events that occurred prior to their admission, especially as medical consultations might blend with in-hospital consultations. This process could be even more challenging for patients who have already started chemotherapy (as was the case of most of our retest participants) because common secondary effects of chemotherapy include memory loss and difficulty concentrating [42]. These findings suggest that to minimise recall bias when assessing delay, the patients should be interviewed as early as possible, as has been suggested in previous studies [12,31].

Recall bias also seems to explain the poor external consistency scores of some other questionnaire items, including symptoms present when the patient first arrived at INCAN, the diagnosis offered by the first doctor consulted, the tests requested by this first doctor, and the time that passed from identification of the problem until the patient told someone about the problem. The remaining poor test-retest consistency scores could be explained by changes in these items over time. The first interview took place before the cancer diagnosis, while the second interview took place after treatment had begun. Items with poor consistency that could have changed over time include use of alternative medicine, knowing a person with cancer and knowledge of recommended breast cancer screening practices.

In regard to the length of the intervals reported in our findings, the median total interval was very prolonged for our study population (median: 234.5 days) and the main delays seem to be presenting within the provider interval (median: 151 days). This is similar to findings of studies that have been done in other Latin American countries. For example, another Mexican study that was done with a small sample of breast cancer patients (n=32) with public health insurance reported a mean total interval of 8.4 months [43]. A Colombian study of 1106 breast cancer patient files reported a median time from the first medical consultation to diagnosis confirmation (diagnosis interval) of 91 days [44] and a Brazilian study with 104 patients reported a median diagnosis interval of 6.5 months [45].

Another matter that we would like to briefly discuss is related to whether a self-complete tool could have provided a more objective way of administering the questionnaire. Such a tool could certainly reduce inter-observer variability and response bias [30]. It has been shown, however, that self-complete tools are difficult for undereducated populations (like our study population) to use [36,37]. This strategy would have most likely yielded a high rate of incomplete and inadequately filled-out questionnaires.

One limitation of our study is that external consistency measures are not available for some items because these items were identified as relevant only after the second pilot study. Because these items are “patient perceptions of barriers within the provider interval”, we hypothesise that they are likely to have reliabilities similar to those found for “perceptions of barriers within the patient interval” (moderate; between 0.4 and 0.75).

One more limitation was the impossibility of constructing scales for the social network of support for medical attention and health service utilisation. Another limitation was the lack of correlation between most of the social network items and the delay intervals. Nevertheless, we think that it is still premature to decide which of these items should be kept or discarded before the instrument is tested in a greater and more heterogeneous sample with higher levels of education, formal employment and higher socioeconomic status.

A disadvantage of the instrument is that its application is time-consuming, especially for older participants and those with low levels of education. On the other hand, it has high acceptability for patients, especially if it is administered when they first arrive at the hospital, before they see the breast specialist.

Conclusions

On the basis of our analyses, we conclude that the Breast Cancer Delay Questionnaire is a valid, reliable and sensitive measure of the total, patient and provider intervals and the predisposing factors of delay in uninsured breast cancer patients treated at a public institution in Mexico. We think it could be useful in other settings, with similar populations, although it would have to be contextually adapted.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

KUS conceived and designed the study, collected data, performed the analysis, interpreted the results and drafted the manuscript. IPB contributed in the study design, directed and supervised data analysis, contributed in the interpretation of results and critically reviewed the manuscript for important intellectual content. CIC contributed in the study design and critically reviewed the manuscript for important intellectual content. All authors read and approved the final manuscript.

Authors’ information

KUS is a medical doctor with a Master’s Degree and a PhD in Health Systems. This research was part of her PhD research thesis. IPB is a medical doctor and archaeologist with a Master’s Degree in Clinical Epidemiology and a PhD in Medical Anthropology. CIC is a sociologist with a Master’s Degree in Medical Sociology and a PhD in Health Systems.

Acknowledgements

This study was supported by a grant from CONACYT (CONACYT/SSA/IMSS/ISSSTE SALUD-2007-C01-69439) and by the National University of Mexico (UNAM). The authors would like to thank Eduardo Lazcano-Ponce and Rebeca Aguirre-Hernández for their helpful comments in the revision of early versions of the questionnaire; Silvia Marmolejo-Valle, Sandra González-Hernández and Minea Sánchez-Crispín for their help with questionnaire applications; and the Breast Tumours Department team of oncologists and nurses at the Mexican National Cancer Institute, specially doctors Eduardo Maafs and Enrique Bargalló, for their support in patient recruitment. We would also like to thank the BMC Cancer reviewers for their most useful comments on earlier versions of this manuscript.

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v1.2. IARC CancerBase No 10. Int Agency Res Cancer: Cancer incidence and mortality worldwide; 2010. OpenURL

  2. American Cancer Society: Breast Cancer Facts and Figures. American Cancer Society, Inc: Atlanta; 2009–2010. OpenURL

  3. Dirección General de Epidemiología (DGE): Base de datos del Registro Histopatológico de Neoplasias Malignas 2004–2006 (RHNM). México: Secretaría de Salud: Sistema Nacional de Vigilancia Epidemiológica (SINAVE); 2004–2006. PubMed Abstract OpenURL

  4. Mohar A, Bargallo E, Ramirez MT, Lara F, Beltran-Ortega A: Available resources for the treatment of breast cancer in Mexico].

    Salud Publica Mex 2009, 51(2):s263-269. PubMed Abstract | Publisher Full Text OpenURL

  5. López-Carrillo LS-LL, Torres-Sánchez L: Breast cancer examination in Mexico: summary of the results from the National Survey of Reproductive Health.

    Salud Publica Mex 2009, 51(2):s345-349. PubMed Abstract | Publisher Full Text OpenURL

  6. Unger-Saldaña K, Infante-Castañeda C: Is Breast Cancer Delay really the patient’s fault? In Relational Concepts in Medicine. Oxford, United Kingdom: Interdisciplinary Net: 1st edition. Edited by Deng M, Raia F, Vaccarella M; 2011. PubMed Abstract | Publisher Full Text OpenURL

  7. Facione NC: Delay versus help seeking for breast cancer symptoms: a critical review of the literature on patient and provider delay.

    Soc Sci Med 1993, 36(12):1521-1534. PubMed Abstract | Publisher Full Text OpenURL

  8. Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA: Factors predicting delayed presentation of symptomatic breast cancer: a systematic review.

    Lancet 1999, 353(9159):1127-1131. PubMed Abstract | Publisher Full Text OpenURL

  9. Unger-Saldaña K, Infante-Castañeda C: Delay of medical care for symptomatic breast cancer: A literature review.

    Salud Publica Mex 2009, 51(S2):S270-S285. PubMed Abstract | Publisher Full Text OpenURL

  10. Montazeri A, Ebrahimi M, Mehrdad N, Ansari M, Sajadian A: Delayed presentation in breast cancer: a study in Iranian women.

    BMC Womens Health 2003, 3(1):4. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  11. Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H: Patient delay and stage of diagnosis among breast cancer patients in Germany – a population based study.

    Br J Cancer 2002, 86(7):1034-1040. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  12. Burgess CC, Potts HW, Hamed H, Bish AM, Hunter MS, Richards MA, Ramirez AJ: Why do older women delay presentation with breast cancer symptoms?

    Psychooncology 2006, 15(11):962-968. PubMed Abstract | Publisher Full Text OpenURL

  13. Barber MD, Jack W, Dixon JM: Diagnostic delay in breast cancer.

    Br J Surg 2004, 91(1):49-53. PubMed Abstract | Publisher Full Text OpenURL

  14. Sainsbury R, Johnston C, Haward B: Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis.

    Lancet 1999, 353(9159):1132-1135. PubMed Abstract | Publisher Full Text OpenURL

  15. Montella M, Crispo A, D’Aiuto G, De Marco M, de Bellis G, Fabbrocini G, Pizzorusso M, Tamburini M, Silvestra P: Determinant factors for diagnostic delay in operable breast cancer patients.

    Eur J Cancer Prev 2001, 10(1):53-59. PubMed Abstract | Publisher Full Text OpenURL

  16. Arndt V, Sturmer T, Stegmaier C, Ziegler H, Becker A, Brenner H: Provider delay among patients with breast cancer in Germany: a population-based study.

    J Clin Oncol 2003, 21(8):1440-1446. PubMed Abstract | Publisher Full Text OpenURL

  17. Caplan LS, Helzlsouer KJ, Shapiro S, Wesley MN, Edwards BK: Reasons for delay in breast cancer diagnosis.

    Prev Med 1996, 25(2):218-224. PubMed Abstract | Publisher Full Text OpenURL

  18. de Nooijer J, Lechner L, de Vries H: Social psychological correlates of paying attention to cancer symptoms and seeking medical help.

    Soc Sci Med 2003, 56(5):915-920. PubMed Abstract | Publisher Full Text OpenURL

  19. Facione NC, Miaskowski C, Dodd MJ, Paul SM: The self-reported likelihood of patient delay in breast cancer: new thoughts for early detection.

    Prev Med 2002, 34(4):397-407. PubMed Abstract | Publisher Full Text OpenURL

  20. Burgess CC, Ramirez AJ, Richards MA, Love SB: Who and what influences delayed presentation in breast cancer?

    Br J Cancer 1998, 77(8):1343-1348. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  21. Nosarti C, Crayford T, Roberts JV, Elias E, McKenzie K, David AS: Delay in presentation of symptomatic referrals to a breast clinic: patient and system factors.

    Br J Cancer 2000, 82(3):742-748. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  22. Neal RD, Pasterfield D, Wilkinson C, Hood K, Makin M, Lawrence H: Determining patient and primary care delay in the diagnosis of cancer - lessons from a pilot study of patients referred for suspected cancer.

    BMC Fam Pract 2008, 9:9. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  23. Lynch BM, Youlden D, Fritschi L, Newman B, Pakenham KI, Leggett B, Owen N, Aitken JF: Self-reported information on the diagnosis of colorectal cancer was reliable but not necessarily valid.

    J Clin Epidemiol 2008, 61(5):498-504. PubMed Abstract | Publisher Full Text OpenURL

  24. Samet JM, Hunt WC, Lerchen ML, Goodwin JS: Delay in seeking care for cancer symptoms: a population-based study of elderly New Mexicans.

    J Natl Cancer Inst 1988, 80(6):432-438. PubMed Abstract | Publisher Full Text OpenURL

  25. Neal RD, Allgar VL: Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the “National Survey of NHS Patients: Cancer”.

    Br J Cancer 2005, 92(11):1971-1975. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  26. Leydon GM, Bynoe-Sutherland J, Coleman MP: The journey towards a cancer diagnosis: the experiences of people with cancer, their family and carers.

    Eur J Cancer Care (Engl) 2003, 12(4):317-326. Publisher Full Text OpenURL

  27. Hansen R, Olesen F, Sorensen H, Sokolowski I, Sondergaard J: Socioeconomic patient characteristics predict delay in cancer diagnosis: a Danish cohort study.

    BMC Health Serv Res 2008, 8:49. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  28. Feinstein AR: Clinimetrics. New Haven: Yale University Press; 1987. OpenURL

  29. Andersen R, Vedsted P, Olesen F, Bro F, Soendergaard J: Patient delay in cancer studies: a discussion of methods and measures.

    BMC Health Serv Res 2009, 9(1):189. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  30. Johnson TP, O’Rourke DP, Burris JE, Warnecke RB: An investigation of the effects of social desirability on the validity of self reports of cancer screening behaviors.

    Med Care 2005, 43(6):565-573. PubMed Abstract | Publisher Full Text OpenURL

  31. Porta M, Malats N, Belloc J, Gallen M, Fernandez E: Do we believe what patients say about their neoplastic symptoms? An analysis of factors that influence the interviewer’s judgement.

    Eur J Epidemiol 1996, 12(6):553-562. PubMed Abstract | Publisher Full Text OpenURL

  32. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ: Influence of delay on survival in patients with breast cancer: a systematic review.

    Lancet 1999, 353(9159):1119-1126. PubMed Abstract | Publisher Full Text OpenURL

  33. Cárdenas-Sánchez J, Sandoval-Guerrero F: Segunda Revisión del Consenso Nacional sobre el diagnóstico y tratamiento del Cáncer Mamario, México 2005.

    Gaceta Mexicana de Oncología 2006, 5:2. OpenURL

  34. Streiner DL, Norman GR: Health measurement scales: a practical guide to their development and use. 2nd edition. Oxford: Oxford Medical Publications; 1995. OpenURL

  35. Unger-Saldana K, Infante-Castaneda CB: Breast cancer delay: A grounded model of help-seeking behaviour.

    Soc Sci Med 2011, 72(7):1096-1104. PubMed Abstract | Publisher Full Text OpenURL

  36. Lopez-Vazquez E, Marvan ML: [Validation of a scale measuring coping with extreme risks].

    Salud Publica Mex 2004, 46(3):216-221. PubMed Abstract | Publisher Full Text OpenURL

  37. Gongora E: Los enfrentamientos a los problemas y el papel del control. una visión etnopsicológica en un ecosistema con tradición (Master's degree thesis), Universidad Nacional Autónoma de México (UNAM), Mexico City; OpenURL

  38. Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, Campbell C, Andersen RS, Hamilton W, Olesen F, et al.: The Aarhus statement: improving design and reporting of studies on early cancer diagnosis.

    Br J Cancer 2012, 106(7):1262-1267. PubMed Abstract | Publisher Full Text OpenURL

  39. Streiner DL, Norman GR: “Precision” and “accuracy”: two terms that are neither.

    J Clin Epidemiol 2006, 59(4):327-330. PubMed Abstract | Publisher Full Text OpenURL

  40. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC: Quality criteria were proposed for measurement properties of health status questionnaires.

    J Clin Epidemiol 2007, 60(1):34-42. PubMed Abstract | Publisher Full Text OpenURL

  41. Deveillis R, In Scale Development: Guidelines in scale development. CA: Newbury Park: Theory and applications. Edited by Deveillis R; 1991. OpenURL

  42. Mitchell T: The social and emotional toll of chemotherapy - patients’ perspectives.

    Eur J Cancer Care (Engl) 2007, 16(1):39-47. Publisher Full Text OpenURL

  43. Bright K, Barghash M, Donach M, de la Barrera MG, Schneider RJ, Formenti SC: The role of health system factors in delaying final diagnosis and treatment of breast cancer in Mexico City, Mexico.

    Breast 2011, 20(Suppl 2):S54-59. PubMed Abstract | Publisher Full Text OpenURL

  44. Piñeros M, Sánchez R, Perry F, García OA, Ocampo R, Cendales R: Demoras en el diagnóstico y tratamiento de mujeres con cáncer de mama en Bogotá.

    Colombia. Salud Pública de México (In Spanish) 2011, 53:478-485. OpenURL

  45. Rezende MC, Koch HA, Figueiredo Jde A, Thuler LC: [Factors leading to delay in obtaining definitive diagnosis of suspicious lesions for breast cancer in a dedicated health unit in Rio de Janeiro].

    Revista brasileira de ginecologia e obstetricia: revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 2009, 31(2):75-81. OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/12/626/prepub